Icagen (ICGND) Return on Equity ROE from the third quarter 2019 to third quarter 2018 and annually, average high and low, overall ranking from Sep 30 2019 to Sep 30 2018 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Icagen, Inc.  (ICGND)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Icagen's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Icagen in the third quarter 2019?
Due to the lack of equity, it was not possible to calculate Icagen, Inc.'s return on equity (ROE) in its third quarter 2019

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2019)
III. Quarter		 (Jun 30 2019)
II. Quarter		 (Mar 31 2019)
I. Quarter		 (Dec 31 2018)
IV. Quarter		 (Sep 30 2018)
III. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -14 -11 -12 -13 -11
Return On Equity (TTM) - - - - -
ICGND's Total Ranking # # # # #
Equity (TTM) in Millions -26 -23 -22 -19 -17
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to ICGND Management Effectiveness >> ICGND's 5 Years Annual ROE >> Compare ICGND ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





ICGND Annual Return On Equity (Dec 31 2018)
2018		 (Dec 31 2017)
2017		 (Dec 31 2016)
2016		 (Dec 31 2015)
2015		 (Dec 31 2014)
2014
Total Equity in Millions -19 -9 -4 2 5
Y / Y Equity Change - - - -68.5 % -
Net Income in Millions -13 -6 -6 -9 0
Y / Y Net Income Change - - - - -
Return On Equity - - - -550.77 % 0.99 %

Back to ICGND Management Effectiveness >> ICGND's 5 Years Annual ROE >> Compare ICGND ROE to its Competitors




Annual Roe Comment
Despite deterioration in net income, company improved ROE to in 2018, company improved ROE to 0.99 % compared to the prior year.


More Return On Equity Ratios
Medical Laboratories Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ICGND's' Return on Equity at Yahoo Finance
ICGND's Roe Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ICGND's Competitors
Subscribers only: Roe for Icagen's Suppliers
Subscribers only: Return On Equity for ICGND's Customers




Companies with similar Return On Equity at Sep 30 2019, within Healthcare Sector ROE
Eli Lilly And Company  144.13 %
Orgenesis Inc   133.86 %
Nrc Health  130.25 %
Integrated Biopharma Inc  123.39 %
Mettler toledo International Inc   104.97 %
Tuhura Biosciences Inc   96.90 %
Metavia Inc   90.98 %
Amgen Inc   71.62 %
Zynex inc   71.37 %
Molecular Templates Inc   70.94 %
Ligand Pharmaceuticals Incorporated  67.27 %
Oxford Immunotec Global Plc  65.30 %
Palatin Technologies Inc   63.20 %
Zoetis Inc   63.06 %
Oramed Pharmaceuticals Inc  58.95 %
Iveric Bio Inc   58.48 %
Viskase Holdings inc   54.57 %
Liquidia Corporation  53.85 %
Surgalign Holdings Inc   53.43 %
Arena Pharmaceuticals Inc   52.86 %
3m Company  48.98 %
Siga Technologies Inc  47.82 %
Strongbridge Biopharma plc  45.77 %
Remedent Inc   43.59 %
Vertex Pharmaceuticals Inc  43.50 %
Adaptive Biotechnologies Corporation  42.61 %
Exelixis Inc   42.49 %
Biogen Inc   40.11 %
Lantheus Holdings Inc   39.71 %
Adial Pharmaceuticals Inc   39.47 %

Date modified: 2026-08-29T17:35:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.